Trial · NCT01516879
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in LDL-C at Week 52 | Placebo | 6.83 | Standard Error 1.75 | percent change | |
| Percent Change From Baseline in LDL-C at Week 52 | Evolocumab | -50.14 | Standard Error 1.24 | percent change | |
| Change From Baseline in LDL-C at Week 52 | Placebo | 5.1 | Standard Error 1.9 | mg/dL | |
| Change From Baseline in LDL-C at Week 52 | Evolocumab | -52.7 | Standard Error 1.4 | mg/dL | |
| Percentage of Participants With an LDL-C Response at Week 52 | Placebo | 6.4 | 95% Confidence Interval 4.1 to 10.1 | percentage of participants | |
| Percentage of Participants With an LDL-C Response at Week 52 | Evolocumab | 82.3 | 95% Confidence Interval 78.8 to 85.3 | percentage of participants | |
| Percent Change From Baseline in LDL-C at Week 12 | Placebo | 3.17 | Standard Error 1.31 | percent change | |
| Percent Change From Baseline in LDL-C at Week 12 | Evolocumab | -54.35 | Standard Error 0.96 | percent change | |
| Percent Change From Baseline in Total Cholesterol at Week 12 | Placebo | 2.85 | Standard Error 0.87 | percent change | |
| Percent Change From Baseline in Total Cholesterol at Week 12 | Evolocumab | -32.30 | Standard Error 0.63 | percent change | |
| Percent Change From Baseline in Total Cholesterol at Week 52 | Placebo | 5.26 | Standard Error 1.16 | percent change | |
| Percent Change From Baseline in Total Cholesterol at Week 52 | Evolocumab | -28.18 | Standard Error 0.84 | percent change | |
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52 | Placebo | 8.44 | Standard Error 1.68 | percent change | |
| Percent Change From Baseline in Non-high-density Lipoprotein Cholesterol (Non-HDL-C) at Week 52 | Evolocumab | -41.82 | Standard Error 1.21 | percent change | |
| Percent Change From Baseline in Apolipoprotein B at Week 52 | Placebo | 2.94 | Standard Error 1.41 | percent change | |
| Percent Change From Baseline in Apolipoprotein B at Week 52 | Evolocumab | -41.26 | Standard Error 1.02 | percent change | |
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52 | Placebo | 6.47 | Standard Error 1.37 | percent change | |
| Percent Change From Baseline in the Total Cholesterol/HDL-C Ratio at Week 52 | Evolocumab | -30.67 | Standard Error 0.99 | percent change | |
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52 | Placebo | 4.46 | Standard Error 1.50 | percent change | |
| Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 52 | Evolocumab | -41.75 | Standard Error 1.09 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01516879/results